Screener
Beam Therapeutics BEAM Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (3,494) | (3,297) |
| Deferred revenue | (6,355) | (7,470) |
| Other long-term liabilities | 134 | (89) |
| Net cash provided by (used in) operating activities | (128,513) | (103,884) |
| Investing activities | ||
| Purchases of property and equipment | (2,232) | (3,065) |
| Purchases of marketable securities | (153,792) | (339,169) |
| Maturities of marketable securities | 181,293 | 217,145 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's operating cash flow?
- Beam Therapeutics (BEAM) reported operating cash flow of -$128.51M in Q1 2026.
- How has Beam Therapeutics's operating cash flow changed year-over-year?
- Beam Therapeutics's operating cash flow decreased by 23.7% year-over-year, from -$103.88M to -$128.51M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Beam Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude